
Opinion|Videos|August 16, 2024
Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting
Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- In your clinical practice, are there specific situations in which you would choose serum, urine and/or tissue biomarkers? If so, can you expand on when you might use them?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5
















